natgillin/translations-raw huggingface dataset:
In certain embodiments, control parameters for the control system include air pressure in tires, ignition point, stop of engine run when there is a stop sign, additional cooling of internal combustion engine and/or super charging air. 
Regulacija u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što su parametri kontrole tlak u gumama, vrijeme paljenja, gašenje motora prilikom zaustavljanja kod signala za zaustavljanje, specijalno hlađenje motora i/ili zrak za motor.
cycloalkylene with 5 to 7 carbon atoms into cycloalkylene ring, the ring being optionally substituted with side chains T1, wherein T1 is straight or branched C1-C10 alkyl, preferably CH3; b) 
- cikloalkilen s 5 do 7 ugljikovih atoma u cikloalkilenskom prstenu, a prsten može biti supstituiran s bočnim lancima Ti, gdje je T; ravni ili razgranati Ci-Croalkil, b)
The method of claim 12, further comprising the step of applying a surface layer over the capping layer, the surface layer comprising asphalt or concrete or ballast or granular material. The method of claim 12, further comprising removing soil to expose the weak subgrade. 
Postupak prema zahtjevu 11, naznačen time što nadalje obuhvaća korak nanošenja površinskog sloja (100) preko pokrovnog sloja (90), površinski sloj (100) sadrži asfalt ili beton ili balast ili granulirani materijal, ili nadalje obuhvaća uklanjanje tla kako bi se otkrila slaba podloga.
fixing the cells and, optionally, permeabilizing the cells with a detergent; 
fiksiranja stanica i, izborno, permeabiliziranja stanica detergentom;
operating the motor of the first linear mechanical actuator system independently of the motor of the second linear mechanical actuator system; and 
konstruiranju prvog i drugog linearnog mehaničkog aktuatorskog sustava (214, 215), koji trebaju raditi u zajedničkom kućištu (220);
A double stranded RNAi agent that inhibits the expression of Proprotein convertase subtilisin kexin 9 (PCSK9) in a cell, wherein said double stranded RNAi agent comprises a sense strand complementary to an antisense strand forming a double stranded region, wherein said antisense strand comprises a region complementary to part of an mRNA encoding PCSK9, wherein each strand is independently about 14 to about 30 nucleotides in length, wherein said antisense strand comprises at least 19 contiguous nucleotides of the nucleotide sequence 5′-ACAAAAGCAAAACAGGUCUAG-3′ (SEQ ID NO: 412) and said double stranded RNAi agent is represented by formula (III): 
0Dvolančano RNAi sredstvo koje je sposobno inhibirati ekspresiju proprotein konvertaze subtilizin/keksin 9 (PCSK?) u stanici, pri čemu navedeno dvolančano RNAi sredstvo sadrži: (a) sense lanac komplementaran sa antisense lancem, pri čemu navedeni antisense lanac sadrži regiju komplementarnu s dijelom mRNA koja kodira PCSKO, pri čemu je svaki lanac duljine oko 17 do oko 30 nukleotida, pri čemu navedeni antisense lanac sadrži barem 17 nukleotida iz sekvence nukleobaze ACAAAAGCAAAACAGGUCUAG (SEQ ID NO: 412) i dvolančano RNAi sredstvo je predstavljeno s formulom (III): sense:
The compound according to claim 1, wherein the pharmaceutically acceptable salt is selected from the group consisting of the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzensulfonate, p-toluenesulfonate and pamoate. 
Spoj prema bilo kojem od prethodnih zahtjeva, gdje je farmaceutski prihvatljiva sol izabrana iz skupine koja se sastoji od hidroklorida, hidrobromida, hidrojodida, nitrata, sulfata, bisulfata, fosfata, kiselinskog fosfata, izonikotinata, acetata, laktata, salicilata, citrata, tartrata, pantotenata, bitartrata, askorbata, sukcinata, maleata, gentizinata, fumarata, glukonata, glukaronata, saharata, formata, benzoata, glutamata, metansulfonata, etansulfonata, benzensulfonata, p-toluensulfonata i pamoata.
The first and second detaching means can be mechanically coupled with a transfer movement of the extraction module from the closed state to the opened state such that one of the first and second detaching means is activated at a defined time after the activation of the respectively other detaching means. 
Prva i druga sredstva za odvajanje mogu biti mehanički povezana s kretanjem pri premještanju modula za ekstrakciju iz zatvorenog položaja u otvoreni položaj, tako da se aktivira jedan od prvog i od drugog elementa za odvajanje u neko određeno vrijeme nakon aktiviranja odgovarajućeg onog drugog sredstva za odvajanje.
optionally converting the telmisartan to its pharmaceutically acceptable salts. 
(D) izbornom prevođenju telmisartana u njegove farmaceutski prihvatljive soli.
to 6 weight percent of wet refuse, 
0,5 do 6 % masenog udjela vlažnog otpada,
The storage system according to claim 7, wherein at least one of the grid structures is a consolidation grid, wherein the consolidation grid is a grid for storing a plurality of bins. 
Sustav za skladištenje sukladno zahtjevu 7 pri čemu je najmanje jedna struktura rešetke je vezna struktura rešetke.
isolating and/or purifying the immunoglobulin single variable domain according to any of claims 1 to 6, a polypeptide according to any claims 7 to 8, a compound or construct according to any of claims 9 to 10, that is such that it can be obtained by expression of a nucleic acid or nucleotide sequence encoding the same, or a composition according to claim 13, thus obtained. 
Postupak za pripremanje i/ili generiranje trovalentnog konstrukta prema bilo kojem od patentnih zahtjeva 1 do 9, naznačen time što navedeni postupak obuhvaća barem korake povezivanja jednovalentnih sekvenci aminokiseline sadržanih u polipeptidu, spoju ili konstruktu prema bilo kojem od zahtjeva 1 do 9 i na primjer jednu ili više poveznica.
The crystalline polymorph of Claim 1 further characterized by a DSC endotherm in the range of 174°C to 186°C. 
Kristalni polimorf u skladu s patentnim zahtjevom 1, naznačen time što dodatno ima DSC endotermu u rasponu od 174 *C do 186 *C.
The use According to any one of the preceding claims, wherein said effective therapeutic amounts of ET-743 and PLD are to be administered as part of the same medicaments or are provided as separate medicaments to be administered at the same time or at different times. 
Primjena prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time što se navedene efikasne terapeutske količine ET-743 i PLD primjenjuju kao dio istih lijekova ili su osigurane kao odvojeni lijekovi koji će se primjenjivati u isto vrijeme ili u različito vrijeme.
3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for use according to claim 3, which is prepared to be administered for 21 days followed by seven days rest in a 28 day cycle. 
-(4-Amino-1-okso-1,3-dihidroizoindol-2-il)piperidin-2,6-dion, namijen upotrebi u skladu s patentnim zahtjevom 3, naznačen time što ga se pripravlja za primjenu u trajanju od 21 dan, za čim slijedi sedmodnevni odmor, u ciklusu od 28 dana.
• Check phase LV3) Check of the state condition of the node n: if it respects the first condition (a) it accesses L/a1, if it respects the second condition (b) it accesses L/a8, if it respects the third condition (c) it accesses L/a9; 
Kontrolna faza LV3) provjeri uvjet režima čvora n: ako odgovara prvom uvjetu (a) pristupa L/al, ako odgovara drugom uvjetu (b) pristupa L/a8, ako odgovara trećem uvjetu (c) pristupa L/a9;
The disposable lens may be incorporated in the tubular member, so that the surgeon only has to connect the sheath device to the endoscopic instruments needed for the operation and connect the lens to a camera. 
Leće koje se mogu odbaciti mogu biti ugrađene u neki element koji ima oblik cijevi, tako da kirurg treba samo spojiti uređaj za omatanje na endoskopski instrument koji je potreban za operaciju i spojiti leću na kameru.
at least 5% of the cells in the population express on their surfaces detectable levels of CD126. 
(x) najmanje 5 % stanica u populaciji na svojoj površini izražava uočljive razine CD126.
The reaction mixture is poured into ice cold water (40 mL) and extracted with EtOAc, washed with brine, dried (Na2SO4), filtered and evaporated in vacuo. 
Reakcijsku smjesu se prelije u ledeno hladnu vodu (40 ml) i ekstrahira s EtOAc, ispere sa zas. otopinom NaCl, osuši (Na2S04), profiltrira i ispari u vakuumu.
The dosage regimen of the present invention may alternatively be described in terms of administration of a series of transdermal dosage forms comprising incremental dosage increases of buprenorphine. 
Režim doziranja iz ovog izuma može se alternativno opisati u smislu davanja niza transdermalnih oblika doziranja koji sadrže povećavajuće doze buprenorfina.
wherein the transfer mechanism includes at least one mechanical arm selectively moveable between a retracted configuration and an expanded configuration. The portable cooking and delivery system of claim 1 wherein at least one of the ovens includes an ejector moveable between a retracted configuration and an expanded configuration, wherein movement of the ejector from the retracted configuration to the expanded configuration moves the contents of the oven (210) out of the oven without the contents being touched by a human. 
Postupak prema zahtjevu 9, naznačen time, da najmanje jedan od štednjaka (210) obuhvaća uređaj za izbacivanje koji je pomičan između uvučene konfiguracije i rastegnute konfiguracije, te time, da nadalje obuhvaća sljedeće: pomicanje uređaja za izbacivanje (246) iz uvučene konfiguracije prema rastegnutoj konfiguraciji, u svrhu pomicanja sadržina štednjaka izvan štednjaka, bez doticaja ljudskih ruku sa sadržajem.
Recombinant Human Serono 
Rekombinantni humani hormon rasta
The pharmaceutical composition according to any one of claims 1-2, wherein the antisense strand comprises SEQ ID NO:127, and the sense strand comprises SEQ ID NO:60; wherein the antisense strand further comprises 2'-O-methyl modified ribonucleotides at positions 1, 3, 5, 9, 11, 13, 15, 17, and 19; a 2'-5'-ribonucleotide in position 7; and a C3Pi-C3OH non-nucleotide moiety covalently attached at the 3'-terminus; and wherein the sense strand further comprises five consecutive 2'-5'-ribonucleotides in the 3'-terminal positions 15, 16, 17, 18, and 19; a C3Pi non-nucleotide moiety covalently attached at the 3'-terminus; and an inverted abasic moiety covalently attached at the 5'-terminus. 
Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1-2, naznačen time što protusmisleni lanac sadrži SEQ ID NO:127, a smisleni lanac sadrži SEQ ID NO:60; gdje protusmisleni lanac dodatno sadrži 2'-O- metilom modificirane ribonukleotide na položajima 1, 3, 5, 9, 11, 13, 15, 17, te 19; 2'-5'-ribonukleotid na položaju 7; 1 C3Pi-C30H nenukleotidni ostatak kovalentno vezan na 3'-kraju; te gdje smisleni lanac dodatno sadrži pet uzastopnih 2'-5'-ribonukleotida na 3'-terminalnim položajima 15, 16, 17, 18, te 19; C3Pi nenukleotidni ostatak kovalentno vezan na 3'-kraju; i imnvertirani nebazni ostatak kovalentno vezan na 5'-kraju.
using an encoding scheme to transmit payload data (36) at the higher data rate; and locating a representation of the encoding scheme in the frame before the transmission of the payload data (36) at the higher data rate. 
Postupak prema zahtjevu 1, naznačen time, da obuhvaća dodatni korak: uporaba kodne sheme u svrhu prijenosa skupova korisničkih informacija (36) uz veću podatkovnu brzinu; i lociranje predstavljanja kodne sheme u okviru prije izvršenja prijenosa skupova korisničkih informacija (36) uz veću podatkovnu brzinu.
Suitable low-substituted hydroxypropyl celluloses are commercially available from Shin-Etsu Chemical Co., Ltd. under the trade names LH-11, LH-20, LH-21, LH-22, LH-30, LH-31 and LH-32. 
Odgovarajuće nisko supstituirane hidroksipropilne celuloze komercijalno su dostupne od Shin-Etsu Chemical Co., Ltd. pod trgovačkim nazivom LH-11, LH-20, LH-21, LH-22, LH-30, LH-31i LH-32.
A nozzle (101) according to claim 1, wherein said distribution members (104) are connected to an end member (110) arranged at an end of the circumferentially and axially extending surface, the end member being arranged to enclose a portion of said surface. 
Mlaznica (101) sukladno Zahtjevu 1, pri čemu su navedeni distribucijski članci (104) povezani s krajnjim člankom (110) organizirani na kraju cirkumferentno 1 aksijalno protežuće površine, krajnji članak postavljen je tako da zatvara dio navedene površine.
A compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein 
Farmaceutski sastav prikladan za oralnu primjenu koji sadrži spoj formule I:
The exenatide for use of any one of claims 1 to 7, wherein the first mcg/day dose is delivered by a first osmotic delivery device and the second mcg/day dose is delivered by a second osmotic delivery device, and delivery of the exenatide from at least the first or the second osmotic delivery device is continuous over the administration period of at least 3 months. 
Eksenatid za uporabu prema bilo kojem od zahtjeva 1 do 7, naznačen time, da se prva doza u ug/dan daje putem prvog osmotskog uređaja za izdavanje i druga doza u ug/dan se daje putem drugog osmotskog uređaja za izdavanje, dok je dostava eksenatida iz najmanje prvog ili drugog osmotskog uređaja za izdavanje, kontinuirana kroz vremenski period primjene od najmanje 3 mjeseca.
In one embodiment of the present invention the solid composition comprises a lyophilized matrix, wherein the lyophilized matrix comprises corticosteroid and an excipient. Suitable excipients include mannitol, xylitol, sorbitol, maltol, maltitol, lactose, sucrose, maltose, and combinations thereof. 
Tableta za oralno disperziranje sukladno patentnom zahtjevu 12, naznačeno time da je ekscipijens odabran iz skupine koju čine manitol, ksilitol, sorbitol, maltol, maltitol, laktozu, saharozu, maltozu, i njihove kombinacije.
To provide even more accurate sampling, according to an advantageous embodiment, a part which can be expanded outwards, such as a balloon part, may be present in the vicinity of the introduction end of the sampler. 
Da bi se osiguralo još točnije uzimanje uzoraka u skladu s jednim naprednijim ostvarenjem, može se u blizini kraja naprave za uzimanje uzorka, kraja koji se uvodi, staviti dio koji se može proširiti prema vanjskoj strani, takav dio kao što je balon,.
The immunogenic compound according to claim 1 comprising a peptide selected from the group consisting of the following formulae (VIa) and (VIb): 
Imunogeni spoj koji sadrži peptid odabran iz skupine koja se sastoji od slijedećih formula (VIa) i (VIb):
A compound according to Claim 1, a salt thereof or a hydrate of the foregoing, wherein R1 represents a group represented by the formula -N(CH3)R11j, wherein R11j represents 1-methylpiperidin-4-yl or 1-ethylpiperidin-4-yl. 
Spoj prema zahtjevu 1, njegova sol ili hidrat navedenog, naznačen time da R' predstavlja skupinu prikazanu sa formulom -N(CH;)R''i, pri čemu R''i predstavlja 1-metilpiperidin-4-il ili 1-etilpiperidin-4-il.
a first pump (2) configured to compress LNG, and to supply the compressed LNG towards a second pump (4); the second pump (4) configured to further compress the LNG at a high pressure and supply the compressed LNG to the high-pressure gas injection engine; and 
Sustav dobave pogonskog plina za brod prema zahtjevu 1, naznačen time da su sredstva za komprimiranje konfiguriranja za izvlačenje LNG iz spremnika LNG (1), stlačivanje izvučenog LNG kod visokog pritiska, te za dovođenje stlačenog LNG prema visokotlačnom plinskom injekcijskom motoru.
is selected from hydrogen, aliphatic, substituted aliphatic, aryl, substituted aryl, heterocyclyl or substituted heterocyclyl; is selected from Table A: 
je izabran od vodika, alifatika, supstituiranog alifatika, arila, supstituiranog arila, heterociklila ili supstituiranog heterociklila; i R10 je izabran od supstituiranog arila u Tabeli A:
The aqueous formulation for use of claim 9 wherein said pharmaceutical composition further comprises 0.1 µg to 10 µg lixisenatide per U insulin glargine. 
Vodena formulacija namijenjena upotrebi u skladu s patentnim zahtjevom 15, naznačena time što navedeni farmaceutski pripravak dodatno sadrži 0,1 µg do 10 µg liksisenatida po jedinici inzulin glargina.
A back support device according to any preceding claims, wherein the back support is made of wood, metal, plastic, reinforced plastic, foamed plastic, a composite material or several materials, preferably in a laminated assembly, preferably wherein the front side of the back support device has a padded quality. 
Sredstvo za naslanjanje prema bilo kojem od prethodnih zahtjeva, naznačeno time, da je sredstvo za naglanjanje napravljeno od drveta, metala, plastike, pojačane plastike, pjenaste plastike, kompozitnog materijala ili od nekoliko materijala, poželjno u sustavom modularnog sklapanja, poželjno da prednja strana sredstva za naslanjanje bude presvučena mekim materijalom.
LACTOFERRIN FOR USE IN THE DIAGNOSIS OR PROGNOSIS OF ALZHEIMER'S DISEASE, OR IN THE DIAGNOSIS OF PARKINSON'S DISEASE 
Postupak za dijagnozu Alzheimerove bolesti kod subjekta koji pokazuje fenokonverziju neurološke bolesti, koji sadrži:
The slurry is filtered and the solid washed with 30% IPA/heptane (2L/kg). 
(e) Smjesa se filtrira i krutina ispire s 30% IPA/heptan (2L/kg).
A process according to claim 1 wherein step a is carried out by reacting a compound of formula Ia with vinyl magnesium bromide or vinyl magnesium chloride to give a compound of formula IIa in the form of diastereomeric mixture. 
Proces prema zahtjevima 1 do 4, naznačen time da se korak a/l provodi reakcijom smjese formule Ia ili Ib s vinilnim magnezij bromidom ili vinil magnezij kloridom, da bi se dobio spoj formule Ila ili IIb u obliku dijasteromerne smjese.
Especially useful fillers include lactose, maltodextrin, mannitol, microcrystalline cellulose, pregelatinized starch, and sucrose esters. 
Kruta oralna farmaceutska formulacija prema zahtjevu 1, naznačena time što je punilo odabrano iz skupine koja sadrži laktozu, maltodekstrin, manitol, mikrokristalnu celulozu, preželatinizirani škrob, te estere saharoze.
<400> 46 A peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 3, 4 and 5, wherein said peptide is 100 or less, 50 or less, 20 or less, or 10 or less amino acids long. 
Peptid koji sadrži aminokiselinsku sekvencu odabranu iz skupine sastavljene od SEK ID BR: 3, 4 1 5, naznačen time, da je navedeni peptid dužine 100 aminokiselina ili manje, 50 aminokiselina ili manje, 20 aminokiselina ili manje, ili 10 aminokiselina ili manje.
The pharmaceutical composition according to claim 1, in the form of a multi-dose dry powder formulation for administration in a multidose dry powder inhaler device calibrated to provide a metered nominal dose of aclidinium equivalent to about 400 micrograms plus/minus 10% aclidinium bromide, b) an emitted dose of aclidinium equivalent to 360 micrograms plus/minus 35% aclidinium bromide, or c) a fine particle dose of aclidinium equivalent to 120 micrograms plus/minus 35% aclidinium bromide. 
Farmaceutski pripravak za primjenu prema zahtjevu 1, u obliku formulacije suhog praha za više doza namijenjenu za primjenu u višedoznom inhalatoru suhog praha kalibriranom da isporuči odmjerenu nominalnu dozu aklidinija jednaku 400 mikrograma (plus/minus 10 %) aklidinijevog bromida. Farmaceutski pripravak za primjenu prema bilo kojem od prethodnih zahtjeva, naznačen time, što (a) farmaceutski prihvatljiva sol aklidinija je aklidinijev bromid i/ili (b) farmaceutski prihvatljivi nosač su čestice laktoze.
Apparatus according to any of the preceding claims wherein the one or more elongate sheets of the belt portion (15) are adapted to be releasably connected along longitudinal edges (17, 18) thereof by a slidable connector means (34, 36). 
Uređaj prema zahtjevu 1, naznačen time da su jedna ili više uzdužnih ploha (15) spojene duž njihovih slobodnih krajeva pomoću kliznih spojnih sredstava (34, 36) prilagođena na način da se mogu odspojiti.
The compound or salt of claim 1, wherein the compound is 6,8-(dimethyl-D6)-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid, or a salt thereof. 
Deuterirani benzopiranski spoj ili farmaceutski prihvatljiva sol prema patentnom zahtjevu 2, naznačeno time što je spoj 6,8-dibromo-5,7-(dimetil -D6)-2-(trifluorometil)-2H-kromen-3-karboksilna kiselina ili njegova sol.
The gaming system of claim 1 further comprising a video adapter in communication with said projector. 
Sustav igranja prema patentnom zahtjevu 1 naznačen time da nadalje sadrži video adapter (140) u komunikaciji s projektorom (120; 550).
A method of treating IL-17-related inflammation in a human patient in need thereof, comprising administering to the patient a single or divided 70 to 1,000 mg dose of the pharmaceutical formulation of any of embodiments 811 to 836. 
Farmaceutska formulacija prema bilo kojem od zahtjeva 1-3 naznačena time da je za upotrebu u postupku liječenja psorijaze kod humanog pacijenta, pri čemu je protutijelo u dozi od 70, 140, 210 ili 280 mg.
The composition of claim 18, wherein the glidant is selected from the group consisting of magnesium stearate, silica derivatives, such as colloidal silica, pyrogenic silica, hydrated sodium silicoaluminate, colloidal silicon dioxide, talcum and mixtures thereof, preferably magnesium stearate, colloidal silica or talcum. 
Pripravak prema zahtjevu 12, gdje se sredstvo za klizanje odabire iz skupine koju čine magnezijev stearat, derivati silike, kao koloidna silika, pirogena silika, hidrirani natrijev silikoaluminat, koloidni silicijev dioksid, talk i njihove smjese, poželjno magnezijev stearat, koloidna silika ili talk.
The composition according to claim 1, wherein component (A) is 3difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl) amide and component (B2) is selected from the group consisting of difenoconazole, ipconazole, prothioconazole, tebuconazole, propiconazole, cyproconazole, and epoxiconazole. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1Hpirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) spoj koji je izabran izmedu slijedećeg: difenokonazola, ipkonazola, protiokonazola, tebukonazola, epoksikonazola, propikonazola i kiprokonazola.
The method according to claim 1, wherein a proportion of genomes from the at least two different baculovirus species is 1:1. A method for producing mixed OBs comprising the steps of: co-infecting insect larvae with two different baculovirus species, by simultaneous inoculation, or sequential inoculation with a delay of time inferior to the time necessary for the manifestation of the signs of the first infection, and 
Postupak proizvodnje miješanih OB u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time što se sastoji u koracima a) suinficiranja ličinki kukaca s dvije različite vrste bakulovirusa, istodobnim inokuliranjem, ili uzastopnim inokuliranjem, uz vrijeme odgađanja kraće od vremena potrebno za manifestiranje znakova prve infekcije, i b) uzgoja inokuliranih ličinki u odgovarajućim uvjetima do pojave bolesti ili smrti od poliedroze.
Tumour volume was assessed twice weekly by bilateral Vernier calliper measurement, using the formula (length x width) x √(length x width) x (π/6), where length was the longest diameter across the tumour, and width was the corresponding perpendicular. 
Četrnaeast dana nakon implantacije, volumen tumora računat je dva puta tjedno pomoću pomične mjerke Vernier, i formule (duljina x širina) x v (duljna x širina) x (2/6), pri čemu je za duljinu uzet najveći promjer tumora, a širina je bila odgovarajuća duljina okomice.